Doweck I, Gordon C R, Spitzer O, Melamed Y, Shupak A
Motion Sickness and Human Performance Laboratory, Israeli Naval Hyperbaric Institute, Haifa.
J Vestib Res. 1994 May-Jun;4(3):215-20.
In a double-blind, placebo controlled, crossover study, we evaluated the effects of cinnarizine on the VOR of 55 healthy young subjects. VOR was evaluated by the Sinusoidal Harmonic Acceleration (SHA) test at frequencies of 0.01, 0.02, 0.04, 0.08 and 0.16 Hz. There was a reduction in VOR gain in 16 of the 20 SHA trials performed under the influence of cinnarizine alone (25 mg and 50 mg) and cinnarizine 25 mg in combination with 10 mg domperidone or 1 transdermal scopolamine patch. This decrease in VOR gain was significant in only a few SHA trials. Phase lead was not consistently affected by cinnarizine. No notable side effects were found for any of the drug groups. Our findings are in accord with the contention that increased resistance to seasickness produced either by drugs, or by the natural process of habituation to sea conditions, may be reflected by a decrease in VOR gain.
在一项双盲、安慰剂对照的交叉研究中，我们评估了桂利嗪对55名健康年轻受试者前庭眼反射（VOR）的影响。通过正弦谐波加速度（SHA）测试在0.01、0.02、0.04、0.08和0.16Hz频率下评估VOR。在仅受桂利嗪（25mg和50mg）以及25mg桂利嗪与10mg多潘立酮或1片透皮东莨菪碱贴片联合影响下进行的20次SHA试验中，有16次VOR增益降低。这种VOR增益的降低仅在少数SHA试验中具有显著性。相位超前并未始终受到桂利嗪的影响。未发现任何药物组有明显副作用。我们的研究结果与以下观点一致，即药物或对海况的自然适应过程所产生的对晕船抵抗力的增加，可能通过VOR增益的降低来体现。
